Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: An observational cohort study

Diabetes Research and Clinical Practice

Volumn 89, Issue 1, 2010, Pages 46-51

  Negrato, Carlos A ^a   Rafacho, Alex ^a,b   Negrato, Giovana ^a   Teixeira, Marcio F ^a   Araújo, César A R ^a   Vieira, Leila ^a,c   Silva, César A ^a   Date, Sueli K ^a,c   Demarchi, Ana C ^a,c   Gomes, Marilia B ^a,d  

^a Bauru's Diabetics Association   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSIDADE DO SAGRADO CORAÇÃO   (Brazil)

^d STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Diabetes; Gestational diabetes; Insulin therapy; Maternal complications; Neonatal outcomes

Indexed keywords

INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; ANTIDIABETIC AGENT; GLARGINE; INSULIN; LONG ACTING INSULIN;

ADULT; APGAR SCORE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FETUS DEATH; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; INTENSIVE CARE UNIT; JAUNDICE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MICROALBUMINURIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY; PREGNANCY DIABETES MELLITUS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DIABETES COMPLICATIONS; DIABETES, GESTATIONAL; FOLLOW UP; INFANT, NEWBORN, DISEASES; NEWBORN; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; PREVALENCE; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; DIABETES COMPLICATIONS; DIABETES, GESTATIONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INSULIN; INSULIN, NPH; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT; INSULIN, ISOPHANE; INSULIN, LONG-ACTING;

EID: 77953810395     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.03.015     Document Type: Article

References (25)

1. Platt M.J., Stanisstreet M., Casson I.F., Howard C.V., Walkinshaw S., Pennycook S., et al. St Vincent's Declaration 10 years on: outcomes of diabetic pregnancies. Diabetes Med. 2002, 19:216-220.
2. Suhonen L., Hiilesma V., Teramo K. Glycaemic control during early pregnancy and fetal malformations in women with type 1 diabetes mellitus. Diabetologia 2000, 43:79-82.
3. Di Cianni G., Miccoli R., Volpe L., Lencioni C., Del Prato S. Intermediate metabolism in normal pregnancy and in gestational diabetes. Diabetes Metab. Res. Rev. 2003, 19:259-270.
4. Pettitt D.J., Nelson R.G., Saad M.F., Bennet P.H., Knowler W.C. Diabetes and obesity in the offspring of Pima Indian women with diabetes during pregnancy. Diabetes Care 1993, 16:310-314.
5. DCCT: pregnancy outcome in the diabetes control and complications trial. Am. J. Obstet. Gynecol. 1996, 174:1343-1353.
6. Farrel T., Neale L., Cundy T. Congenital anomalies in the offspring of women with type 1, type 2 and gestational diabetes. Diabetes Med. 2002, 19:322-326.
7. Simmons D. The utility and efficacy of the new insulins in the management of diabetes and pregnancy. Curr. Diab. Rep. 2002, 2:331-336.
8. Hirsch I.B. Insulin analogues. N. Engl. J. Med. 2005, 352:174-183.
9. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
10. Hemkens L.G., Grouven U., Bender R., Günster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52:1732-1744.
11. Smith U., Gale E.A. Does diabetes therapy influence the risk of cancer?. Diabetologia 2009, 52:1699-1708.
12. Colhoun H.M. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009, 52:1755-1765.
13. Jonasson J.M., Ljung R., Talbäck M., Haglund B., Gudbjörnsdòttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-1754.
14. Hofmann T., Horstmann G., Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int. J. Toxicol. 2002, 21:181-189.
15. Pollex E.K., Feig D.S., Lubetsky A., Yip P.M., Koren G. Insulin glargine safety in pregnancy a transplacental transfer study. Diabetes Care 2010, 33:29-33. 33.
16. Dolci M., Mori M., Baccetti F. Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison's Disease. Diabetes Care 2005, 28:2084-2085.
17. Di Cianni G., Volpe L., Lencioni C., Chatzianagnostou K., Cuccuru I., Ghio A., et al. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 2005, 28:982-983.
18. Fang Y.M.V., MacKeen D., Egan J.F.X., Zelop C.M. Insulin glargine compared with Neutral Protamine Hagedorn insulin in the treatment of pregnant diabetics. J. Matern. Fetal Neonatal Med. 2009, 22:249-253.
19. Landon M.B., Catalano P.N., Gabbe S.G. Diabetes Mellitus: Normal & Problem Pregnancies 2002, Churchill Livingston, Philadelphia, pp. 1094-1095.
20. Carpenter M., Coustan D. Criteria for screening tests for gestational diabetes. Am. J. Obstet. Gynecol. 1982, 144:768-773.
21. American Diabetes Association: Medical Management of Pregnancy Complicated by Diabetes 2000, American Diabetes Association, Alexandria.
22. Solomon C.G., Graves S.W., Greene M.F., Seely E.W. Glucose intolerance as a predictor of hypertension in pregnancy. Hypertension 1994, 23:717-721.
23. Apgar V. A proposal for a new method of evaluation of the newborn infant. Curr. Res. Anest. Analg. 1983, 32:260-267.
24. Lubchenco L.O., Hansman C., Boyd E. Intrauterine growth in length and head circumference as estimated from live births at gestational ages from 26 to 42 weeks. Pediatrics 1966, 37:403-408.
25. Ceriello A., Esposito K., Piconi L., Ihnat M.A., Thorpe J.E., Testa R., et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57:1349-1354.